Protection provided by hepatitis B vaccine in a Yupik Eskimo population - Results of a 10-year study

Journal of Infectious Diseases

Volumn 175, Issue 3, 1997, Pages 674-677

  Wainwright, Robert B ^a   Bulkow, Lisa R ^a   Parkinson, Alan J ^b   Zanis, Carolyn ^b   McMahon, Brian J ^b  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; CHILD; DRUG EFFICACY; ESKIMO; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; INFANT; INFECTION PREVENTION; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0031017691     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/175.3.674     Document Type: Article

References (14)

1. Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology 1981;1:377-85.
2. Francis DP, Hadler SC, Thompson SE, et al. The prevention of hepatitis B with vaccine: report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann Intern Med 1982;97:362-6.
3. Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986;315:209-14.
4. Coursaget P, Yvonnet B, Chotard J, et al. Seven-year study of hepatitis B vaccine efficacy in infants from an endemic area (Senegal). Lancet 1986;2:1143-5.
5. Krugman S, Davidson M. Hepatitis B vaccine: prospects for duration of immunity. Yale J Biol Med 1987;60:333-8.
6. Hadler SC, Judson FN, O'Malley PM, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991;163:454-9.
7. Goh KT, Tan KL, Kong KH, Don CJ, Chan SH. Comparison of the immune response of four different dosages of a yeast-recombinant hepatitis B vaccine in Singapore children: a four-year follow-up study. Bull World Health Organ 1992;70:233-9.
8. Milne A, Krugman S, Waldon JA, et al. Hepatitis B vaccination in children: five year booster study. N Z Med J 1992;105:336-8.
9. Tabor E, Cairns J, Gerety RJ, Bayley AC. Nine-year follow-up study of a plasma-derived hepatitis B vaccine in a rural African setting. J Med Virol 1993;40:204-9.
10. Milne A, Hopkirk N, Moyes CD. Hepatitis B vaccination in children: persistence of immunity at 9 years. J Med Virol 1994;44:113-4.
11. Heyward WL, Bender TR, McMahon BJ, et al. The control of hepatitis B virus infection with vaccine in Yupik Eskimos. A J Epidemiol 1985;121:914-23.
12. Wainwright RB, McMahon BJ, Bulkow LR, et al. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. JAMA 1989;261,16:2362-6.
13. Wainwright RB, McMahon BJ, Bulkow LR. Protection provided by hepatitis B vaccine in a Yupik Eskimo population - 7 year results. Arch Intern Med 1991;151:1634-6.
14. Hollinger FB, Dreesman GR. Immunobiology of hepatitis viruses. In: Rose NR, Friedman H, Fahey L, eds. Manual of clinical laboratory immunology. 3rd ed. Washington, DC: American Society for Microbiology, 1986:568.